×
0 -0.000474608448030281 -0.00189843379212146 0.00142382534409118 0.00759373516848601 0.00474608448030382 0.0147128618889417 0.0223065970574277
Stock impact report

Capital Market Laboratories (CMLviz) Interviews Invitae’s CEO –Invitae’s Non-Invasive Prenatal Screening Tests Can be a 50% Gross Margin Business

Invitae Corp (NVTA)  More Company Research Source: GlobeNewswire
Last invitae corp earnings: 8/6 04:15 pm Check Earnings Report
PDF LOS ANGELES, June 27, 2019 (GLOBE NEWSWIRE) -- In an interview with Capital Market Laboratories (CMLviz), chief executive officer of Invitae (NYSE:NVTA) Sean George had a clear message: Invitae will never be announcing M&A in an attempt to fill a drop-in revenue. The acquisition of Singular Bio gives Invitae a critical technology that can turn the NIPS business into a 50% gross margin performer once fully integrated into the firm’s process, and if you broke out Invitae's cancer business, it turned a profit as a standalone business as of Q1 of this year.  Read: One-on-One CEO Interview: Invitae (NVTA) Acquires a Critical Technology Media queries Alicia Newman, Director Client Services Capital Market Laboratories support@cmlviz.com Source: Capital Market Laboratories [Read more]
Impact snapshot Event time: NVTA
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last price
VWAP
High:
Max up
High:
Low:
Max down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Opt-in for
NVTA alerts

from News Quantified
Opt-in for
NVTA alerts

from News Quantified